Abstract:Abstract Childhood cancer survivors are at increased risk of subsequent neoplasms (SN), largely considered to be therapy-related. Studies of cancer predisposition genes (CPGs) and risk of SN among long-term survivors are lacking. We characterized germline mutations in CPGs in childhood cancer survivors to determine their contribution to SN risk. Whole genome (30x) and exome (100x) sequencing was performed for 2988 5+ year survivors of childhood cancer (1629 leukemia/lymphoma, 332 CNS, 1027 other solid tumors, 53% male, median follow-up 28 [range 6-55] years). Survivors underwent a comprehensive clinical assessment, treatment exposures were abstracted from medical records, and SN were validated by pathology reports. Germline mutations in 63 CPGs were classified using the American College of Medical Genetics and Genomics guidelines as previously described (Zhang et al. NEJM 2015). Logistic regression, adjusting for age, sex and race, was used to evaluate associations between mutation status, cancer therapy and the SN risk. 1062 SNs were diagnosed in 437 survivors, of whom 98 developed ≥2 histologically distinct SNs. Median age at SN and time to first SN was 38.2 (range 3.3-67.4) and 29.2 (0.9-48.4) years, respectively. Common SNs were basal cell carcinoma (542 in 153 survivors), meningioma (201 in 100), thyroid (64 in 64), and breast cancer (58 in 50). Cumulative incidence of SN at age 45 was 25.5% (95% CI: 22.9-27.9). 169 survivors (5.7%) had a pathogenic/likely pathogenic (P/LP) mutation in a CPG, consisting of 97 single nucleotide variations, 63 insertion/deletions and 9 copy number alterations (49% of mutations not in ClinVar). Frequently mutated genes were: RB1 (n=41), NF1 (n=22), BRCA2 (n=13), BRCA1 (n=12) and TP53 (n=10). Our data confirmed known associations between CPG mutations and specific primary diagnoses including RB1 mutations in 32 of 41 (78%) of bilateral and 7 of 57 (12%) of unilateral retinoblastoma survivors, 22 NF1 (20 of 332 CNS survivors), 4 SUFU (all in medulloblastoma survivors) and 5 WT1 mutations (all in Wilms’ tumor survivors). Analyses revealed novel associations between CPG mutations and SN risk. Among 1326 survivors not exposed to radiation therapy (non-RT), 62 SNs developed in 54 survivors, of which 15 (24.2%) occurred in P/LP mutation carriers. Non-RT exposed survivors with a P/LP mutation had an increased risk of SN (OR=5.6, 95% CI=2.6-12.0, P<0.001) and the odds of developing ≥2 distinct histologic types of SNs was increased by 23.6-fold (95% CI=5.4-102.7, P<0.001). In 1662 RT exposed survivors, P/LP-mutation carriers had an odds ratio of 2.3 (95% CI=0.9-6.0, P=0.08) for developing ≥2 distinct histologic types of SNs. Our findings indicate that a substantial proportion of non-RT exposed childhood cancer survivors who develop one or more SN carry a CPG mutation, and should be referred to genetic testing and counseling services. Citation Format: Zhaoming Wang, Carmen L. Wilson, John Easton, Dale Hedges, Qi Liu, Gang Wu, Michael Rusch, Michael Edmonson, Shawn Levy, Jennifer Q. Lanctot, Eric Caron, Kyla Shelton, Kelsey Currie, Matthew Lear, Heather L. Mulder, Donald Yergeau, Celeste Rosencrance, Bhavin Vadodaria, Yadav Sapkota, Russell J. Brooke, Wonjong Moon, Evadnie Rampersaud, Xiaotu Ma, Shuoguo Wang, Ti-Cheng Chang, Stephen Rice, Andrew Thrasher, Aman Patel, Cynthia Pepper, Xin Zhou, Xiang Chen, Wenan Chen, Angela Jones, Braden Boone, Deo Kumar Srivastava, Chimene A. Kesserwan, Kim E. Nichols, James R. Downing, Melissa M. Hudson, Yutaka Yasui, Leslie L. Robison, Jinghui Zhang. Germline mutations in cancer predisposition genes and risk for subsequent neoplasms among long-term survivors of childhood cancer in the St. Jude Lifetime Cohort [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 3001. doi:10.1158/1538-7445.AM2017-3001

A High-risk Haplotype for Premature Menopause in Childhood Cancer Survivors Exposed to Gonadotoxic Therapy.

A High-Risk Genetic Profile for Premature Menopause (PM) in Childhood Cancer Survivors (CCS) Exposed to Gonadotoxic Therapy: A Report from the St. Jude Lifetime Cohort (SJLIFE) and Childhood Cancer Survivor Study (CCSS).

Abstract 3007: Monogenic and Polygenic Associations with Subsequent Breast Cancer Risk in Survivors of Childhood Cancer: the St. Jude Lifetime Cohort Study (SJLIFE)

Abstract 3001: Germline Mutations in Cancer Predisposition Genes and Risk for Subsequent Neoplasms among Long-Term Survivors of Childhood Cancer in the St. Jude Lifetime Cohort

Pathogenic Germline Mutations in DNA Repair Genes in Combination with Cancer Treatment Exposures and Risk of Subsequent Neoplasms among Long-Term Survivors of Childhood Cancer

Polygenic Risk and Chemotherapy-Related Subsequent Malignancies in Childhood Cancer Survivors: A Childhood Cancer Survivor Study and St Jude Lifetime Cohort Study Report

Interindividual variation in ovarian reserve after gonadotoxic treatment in female childhood cancer survivors - a genome-wide association study: results from PanCareLIFE

Genetic Risk for Subsequent Neoplasms Among Long-Term Survivors of Childhood Cancer.

A Novel Locus Predicts Spermatogenic Recovery among Childhood Cancer Survivors Exposed to Alkylating Agents

Abstract 1562: Germline Polymorphisms in Cancer Stem Cell Genes Associate with Survival among Women with High-Grade Serous Ovarian Cancer

Abstract 6155: Germline variants in cancer susceptibility genes and subsequent neoplasm risks after childhood cancer: A pooled analysis of two large-scale cohorts

Rare coding variants in DNA damage repair genes associated with timing of natural menopause

Effect of Genetic Variation in CYP450 on Gonadal Impairment in a European Cohort of Female Childhood Cancer Survivors, Based on a Candidate Gene Approach: Results from the PanCareLIFE Study

Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study

Polygenic risk scores, radiation treatment exposures and subsequent cancer risk in childhood cancer survivors

Polygenic Determinants for Subsequent Breast Cancer Risk in Survivors of Childhood Cancer: the St Jude Lifetime Cohort Study (SJLIFE).

Abstract 818: Association of Polygenic Risk Score and Menopausal Hormone Therapy for Colorectal Cancer Risk

Premature Menopause, Clonal Hematopoiesis, and Coronary Artery Disease in Postmenopausal Women

Abstract 3462: Mendelian randomization analysis of 27 cardiometabolic trait related polygenic scores identifies genetic risk for cardiometabolic and cardiovascular events in a large prospective study of breast cancer survivors

Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in the Childhood Cancer Survivor Study.

Supplementary Table 3 from Platinum Sensitivity–Related Germline Polymorphism Discovered Via a Cell-Based Approach and Analysis of Its Association with Outcome in Ovarian Cancer Patients